These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 32251022

  • 21. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [Abstract] [Full Text] [Related]

  • 22. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
    Int J Cardiol; 2013 Jun 05; 166(1):147-51. PubMed ID: 22108512
    [Abstract] [Full Text] [Related]

  • 23. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 05; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 24. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 05; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 25. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ, Atrial Arrhythmia Conversion Trial Investigators.
    Circulation; 2008 Mar 25; 117(12):1518-25. PubMed ID: 18332267
    [Abstract] [Full Text] [Related]

  • 26. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs Aging; 2011 Jun 01; 28(6):501-4. PubMed ID: 21639409
    [Abstract] [Full Text] [Related]

  • 27. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D.
    Int J Cardiol; 2013 Oct 30; 169(2):95-6. PubMed ID: 24071384
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C, Blomström P.
    Expert Opin Drug Saf; 2012 Jul 30; 11(4):671-9. PubMed ID: 22632377
    [Abstract] [Full Text] [Related]

  • 29. Effectiveness and Safety Profiles of Vernakalant for Cardioversion of Acute-onset Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Yu C, Li J, Zhao C, Guan Y, Wu D, Sun B, Wang X.
    Clin Ther; 2023 Mar 30; 45(3):218-231. PubMed ID: 36828756
    [Abstract] [Full Text] [Related]

  • 30. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C, Laggner AN, Domanovits H, Spiel AO.
    Europace; 2017 Feb 01; 19(2):233-240. PubMed ID: 28175295
    [Abstract] [Full Text] [Related]

  • 31. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May 01; 21(127):119-22. PubMed ID: 22827000
    [Abstract] [Full Text] [Related]

  • 32. Vernakalant for the conversion of atrial fibrillation: the new kid on the block?
    Conde D, Baranchuk A.
    Ann Noninvasive Electrocardiol; 2014 Jul 01; 19(4):299-302. PubMed ID: 24738652
    [Abstract] [Full Text] [Related]

  • 33. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 15; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 35. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
    Cialdella P, Pedicino D, Santangeli P.
    Recent Pat Cardiovasc Drug Discov; 2011 Jan 15; 6(1):1-8. PubMed ID: 21235460
    [Abstract] [Full Text] [Related]

  • 36. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N, Juhlin T, Öhlin B, Carlson J, Holmqvist F, Platonov PG.
    Ann Noninvasive Electrocardiol; 2015 Mar 15; 20(2):140-7. PubMed ID: 25040826
    [Abstract] [Full Text] [Related]

  • 37. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May 15; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 38. Meta-analysis of effect of vernakalant on conversion of atrial fibrillation.
    Yan H, Aung TT, Guoqiang Z, Zhengnan Z, Lan J, Zhiyu Z.
    BMC Res Notes; 2013 Mar 13; 6():94. PubMed ID: 23497611
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis.
    deSouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R.
    Europace; 2020 Jun 01; 22(6):854-869. PubMed ID: 32176779
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.